Our mRNAi GOLD™ Pipeline Targets

We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area. Our wholly owned pipeline is currently focused in three therapeutic areas of high unmet need: hematology, cardiovascular disease, and rare diseases.

Disease
Target
Discovery
Preclinical
Phase I
Ph II
Ph III
Proprietary/Partnered
clinical Clinical
SLN360
Cardiovascular disease with high Lp(a)
Lp(a)
Silence Logo
SLN124
Thalassemia
TMPRSS6
Silence Logo
SLN124
Myelodysplastic Syndrome
TMPRSS6
Silence Logo
Multiple programs
Undisclosed
Undisclosed
Silence Logo
SLN501
SLN-MNK-2
SLN-MNK-3
Complement-mediated diseases
C3
Undisclosed
Undisclosed
mallinckrodt Logo
SLN-AZ-1
SLN-AZ-2
Undisclosed
Undisclosed
Undisclosed
Undisclosed
astrazeneca Logo